AnneEBorgmanMD

Pediatric Hematology & Oncology • Palo Alto, CA

Physician

Join to view full profile

Are you Dr. Borgman?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 59 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
725 Welch Rd
Palo Alto, CA 94304
Phone+1 650-497-8000
Is this information wrong?

Summary

Dr. Anne Borgman, MD is a pediatric hematologist/oncologist in Palo Alto, California. She is currently licensed to practice medicine in California, Illinois, and Texas.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 1997 - 2000
Baylor College of Medicine (Houston)Residency, Pediatrics, 1994 - 1997
Loyola University Chicago Stritch School of MedicineClass of 1994

Certifications & Licensure

IL State Medical License 2000 - 2026
CA State Medical License 1997 - 2024
TX State Medical License 1996 - 1997

Publications & Presentations

PubMed

Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function.
Bedikian, A.Y., Silverman, J.A., Papadopoulos, N.E., Kim, K.B., Hagey, A.E., Vardeleon, A., Hwu, W., Homsi, J., Davies, M., Hwu, P.> ;J Clin Pharmacol. 2011 Aug
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.
Mauer, A.M., Cohen, E.W., Ma, P.C., Kozloff, M.F., Schwartzberg, L., Coates, A.I., Qian, J., Hagey, A.E., Gordon, G.B.> ;J Thorac Oncol. 2008 Jun
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Fox, E., Maris, J.M., Widemann, B.C., Goodspeed, W., Goodwin, A., Kromplewski, M., Fouts, M.E., Medina, D., Cohn, S.L., Krivoshik, A., Hagey, A.E., Adamson, P.C., Bali...> ;Clin Cancer Res. 2008 Feb 15
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Fox, E., Maris, J.M., Widemann, B.C., Meek, K., Goodwin, A., Goodspeed, W., Kromplewski, M., Fouts, M.E., Medina, D., Cho, S.Y., Cohn, S.L., Krivoshik, A., Hagey, A.E....> ;Clin Cancer Res. 2006 Aug 15
Increasing diversity in pediatric hematology/oncology.
Frugé, E., Lakoski, J. M., Luban, N., Lipton, J. M., Poplack, D. G., Hagey, A., Felgenhauer, J., Hilden, J., Margolin, J., Vaiselbuh, S. R., Sakamoto, K. M.> ;Pediatr Blood Cancer. 2011 Jul 15
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
Hande, K. R., Hagey, A., Berlin, J., Cai, Y., Meek, K., Kobayashi, H., Lockhart, A. C., Medina, D., Sosman, J., Gordon, G. B., Rothenberg, M. L.> ;Clin Cancer Res. 2006 May 1
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Yee, K. W., Hagey, A., Verstovsek, S., Cortes, J., Garcia-Manero, G., O'Brien, S. M., Faderl, S., Thomas, D., Wierda, W., Kornblau, S., Ferrajoli, A., Albitar, M., McK...> ;Clin Cancer Res. 2005 Sep 15
Join now to see all

Press Mentions

NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of DirectorsJanuary 18th, 2023
NextCure Announces New Appointments to Its Board of DirectorsOctober 4th, 2021
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1June 4th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member